AryoGen
 | |
| Private Company | |
| Industry | Pharmaceutical |
| Founded | 2009 |
| Headquarters | Tehran, Iran |
Area served | Worldwide |
Key people |
Dr. Fereidoun Mahboudi Chairman |
| Products | biopharmaceuticals, Monoclonal antibody |
| Revenue |
 US$ 100 million |
Number of employees |
300+ (2015) |
| Website | AryoGen |
AryoGen Pharmed (in Persian: آریوژن فارمد ) is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.[1][2][3]
History
AryoGen is a biopharmaceutical company created on the mandate of Iranian executive branch. It was created a group of scientific experts spun off a well versed Biopharmaceutical company, which formed a totally new entity christened as AryoGen Biopharma which started its production in 2011. It was deemed an issue of national interest due to the importance of the target products on Iran's community health care system, as well as its impact in the region and around the world.
AryoGen is the world's first company to produce biosimilar Blood Coagulation Factor VII, which required a 50 million Euros product investment. Also AryoGen has established a monoclonal antibodies production line amongst only 10 manufacturer of the world.
AryoGen has been change his name to AryoGen Pharmed since 2016.
Products
AryoGen's products include:
- Blood Coagulation factor VII with the name of AryoSeven which is a biosimilar form of Novoseven with multi billion dollars world market and is used for hemophilia patients and other conditions
- Altebrel with the generic name of Etanercept and original trade name of Enbrel which for some years was the no. one in the biopharmaceutical market and is used for treatment of autoimmune diseases
- Zytux with the generic name of Rituximab and original trade name of Rituxan which is an anticancer biomedicine,
- Hercease with the generic name of trastuzumab and original name of Herceptin which is a revolutionary drug in treatment of breast cancer
- Arvestin with the generic name of bevacizumab and original trade name of Avestin and is used for treatment of some sort of cancer.
AryoSeven is now approved by Iranian food and drug organisation and from Aug 2012 is in the market and other biomedicines are closing to the market.
See also
References
- ↑ "IRAN, ISLAMIC REPUBLIC OF : Aryogen produces locally made medicines in Iran; helps Iran save up to $100 mln annually.". Mena Report.
- ↑ World's 2nd factor VII factory opened in Iran. - Mehr News Agency (MNA) | HighBeam Research
- ↑ Iran launches domestic manufacture of anti-hemophilia drug - Trend.Az
External links
- AryoGen - Home
- Hemophilia
- List of biopharmaceutical companies
- Launching domestic manufacture of anti-hemophilia drug
- Related Clinical trials